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CASE PRESENTATIONS
Patient 1. A 50-year-old man with end-stage renal dis-
ease (ESRD) possibly secondary to Fabry disease com-
menced chronic ambulatory peritoneal dialysis (CAPD)
19 months ago. In childhood he presented with acropares-
thesias and pain crises with fever, which were considered
to be of psychosomatic origin. Remission of the symp-
toms occurred when he was 15 years old, but he contin-
ued to have atypical abdominal pain and a low threshold
for pain. In childhood he also developed angiokeratomas.
From the age of 29, he suffered from asthma and since
then has been treated with anti-asthmatic inhalers.
Fifteen years ago he underwent a slit-lamp examina-
tion, in which the typical ophthalmic findings of Fabry
disease (cornea verticilata, lenticular opacities) were ob-
served and the diagnosis of the disease was established.
Eleven years ago, hypertrophic cardiomyopathy with
arrhythmias was treated with anti-arrhythmic agents, in-
cluding amiodarone. Renal insufficiency was detected
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when he was 38 years old. At the time of onset of re-
nal insufficiency, proteinuria was approximately 2500 mg/
24 hours and continued at this level during all the years
of follow-up until the patient reached ESRD, when a
reduction to 300 mg/24 hours was noted. The patient’s
mild to moderate hypertension was well controlled at a
level of 130/84 mm Hg with an angiotensin-converting
enzyme (ACE) inhibitor until 1 year before the onset of
ESRD, when a calcium channel blocker was added. Dur-
ing the 10-year follow-up, the patient’s creatinine clear-
ance (CCr) declined at a rate of 7.9 mL/min/year (Fig. 1).
The CAPD program is 4 × 1 L dialysis fluid with 1.5%
glucose concentration. The small size of the patient
(54 kg body weight and 156 cm height) led to an in-
tolerance of larger intraperitoneal volumes. Before he
commenced CAPD, echocardiography revealed a left
ventricular mass (LVM) of 430 g and an ejection fraction
(EF) of 47%. In view of the renal findings and cardiac
dysfunction, enzyme replacement treatment (ERT) with
intravenous agalsidase beta (Fabrazyme), 1 mg/kg/body
weight initially every other week, was initiated 1 month
after he began CAPD.
Before the commencement of treatment and after 1.5,
3, 6, 12, and 15 months, weekly residual renal creati-
nine clearance (wCrCr) and renal Kt/V urea (wKrt/Vurea)
were determined according to standard equations. Peri-
toneal dialysis adequacy was also estimated by weekly
peritoneal Kt/V urea (wKpt/Vurea) and creatinine clear-
ance (wCpCr). The latter was adjusted for the patient’s size
using a nomogram for body surface area. Table 1 displays
routine laboratory investigation before and after ERT.
The wCrCr rose after 1.5 months of therapy from
29 to 82 L/week/1.73 m2. It remained at approximately
80 L/week/1.73 m2 after 3 and 6 months of therapy; a
decrease to 60 L/week/1.73 m2 was noticed at month 12
and continued until month 15 of therapy [these values
are represented in the figure as Ccr (mL/min)]. Also, the
wKrt/Vurea rose strikingly, from 0.8 to 2.3 after 1.5 months,
remained around 2.0 after 3 and 6 months, dropped to 1.5
after 12 months, and remained stable after 15 months
of treatment. The wCpCr, on the other hand, did not
change significantly during the same period. Similarly,
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Fig. 1. Creatinine clearance values of Patients 1 and 2 before and after
enzyme replacement treatment (ERT).
wKpt/Vurea decreased from 1.6 to 1.1 after 15 months of
treatment. The patient’s residual 24-hour urine volume
rose after the commencement of ERT from 400 mL to ap-
proximately 550 mL. Renal ultrasound showed echogenic
small kidneys of similar size to before the initiation of
CAPD (that is, right, 7.4 cm and left, 7.5 cm). After
15 months of ERT, proteinuria decreased to 198 mg/
24 hours. Net ultrafiltration/day decreased from 1700 mL
to 600 mL. Levels of a-globotriaosylceramide (GL-3)
in the plasma significantly decreased after 6 months of
therapy, from 10.9 lmol/L to 4.0 lmol/L (normal, 1.6 to
3.3 lmol/L). Echocardiography, performed after 18
months of treatment with agalsidase beta, showed a re-
duction of LVM from 430 g to 345 g. The EF also improved
substantially, reaching 79%. The patient’s blood pressure
is 130/80 mm Hg without antihypertensive medications.
He feels much better, has less sensitivity to pain, and men-
tions no pain crises or fever. During the last 15 months, he
has gained approximately 5 kg. It is also noticeable that
he does not need erythropoietin to maintain the accepted
levels of hemoglobin. Table 1 shows his laboratory data
before the initiation of the ERT and after 15 months.
Patient 2. A 51-year-old man, brother of the first pa-
tient, was diagnosed with Fabry disease and referred to
our institution 2 years ago for evaluation of chronic renal
insufficiency (CRI). In childhood he had angiokeratomas
and acroparesthesias, which persisted until age 35. At age
20, when he went into the army, a dermatologist diag-
nosed a “hereditary disease that cannot be treated.” Ten
years ago, the diagnosis of Fabry disease was confirmed by
skin biopsy and slit-lamp examination. At the same time
he started having angina pectoris, and coronary angiogra-
phy revealed one-vessel coronary artery disease. He also
had a hypertrophic myocardium. Two years ago, severe
bradycardia required pacemaker implantation. He also
had signs of chronic obstructive lung disease. Further-
more, he experienced episodes of vertigo and dizziness
and suffered from hypohidrosis and severe high temper-
ature intolerance.
Physical examination was unremarkable apart from
the angiokeratomas on his legs. He was 160 cm tall and
weighed 71 kg. His blood pressure was well controlled
(134/84 mm Hg) with one to two antihypertensive agents.
He had never received an ACE inhibitor. He was about
39 years old when mild CRI was diagnosed (serum crea-
tinine, 1.3 mg/dL). At the same time, he presented with
microalbuminuria (∼150 mg/24 hours), which remained
unchanged during the years of follow-up. During a follow-
up of about 10 years, his CCr decreased at a rate of
2.4 mL/min/year (Fig. 1). Although his CCr was approxi-
mately 45 mL/min, and ultrasound showed that the right
and left kidneys were 10.4 cm and 9.8 cm with cortices
of 15.5 mm and 14.3 mm, respectively, he declined re-
nal biopsy. The likely diagnosis was Fabry nephropa-
thy, and he started treatment with IV agalsidase beta,
1 mg/kg/body weight every other week. The CCr rose
gradually during the 15 months of treatment and reached
65 mL/min; microalbuminuria remained stable at 150 mg/
24 hours, as it was before the start of therapy. This pa-
tient also gained about 4 kg. Echocardiography revealed
parameters similar to his brother’s. The LVM showed
small alterations: from 503 g at the beginning to 490 g
after 18 months. In contrast, the EF increased even after
12 months from 46% to 56% and moreover to 82% after
18 months. Table 1 illustrates his laboratory data before
the initiation of the ERT and after 15 months.
The patient discontinued taking his antihypertensive
medication after 6 months of ERT, and his blood pressure
remains normal at 130/80 mm Hg without therapy. Plasma
GL-3 levels decreased from 9.1 lmol/L to 3.7 lmol/dL.
The patient reported sweating for the first time in his life,
especially of the hands, and he enjoyed his first summer
without suffering from the heat. Moreover, the vertigo
has improved significantly so that he has discontinued the
three medications he was taking for dizziness and vertigo.
DNA analysis, which was performed for both patients
at the Genetic Testing Laboratory of the Mount Sinai
School of Medicine, revealed that the brothers are hemi-
zygotes for Fabry disease with the same missense muta-
tion T385P in exon 7. Detection of plasma a-galactosidase
A (a-Gal A) activity performed immediately before the
start of ERT (in the Department of Biochemistry of
the Academic Medical Center, Amsterdam, The Nether-
lands) revealed similar activities for both patients (0.8 and
0.7 nmol/hour/mL, respectively). Treatment with agalsi-
dase beta was well tolerated by both patients.
DISCUSSION
DR. KOSTAS C. SIAMOPOULOS (Professor of Medicine/
Nephrology, Chief , Division of Nephrology; Department
of Medicine, University of Ioannina, Ioannina, Greece):
Fabry disease is an X-linked metabolic disorder caused
by the deficient activity of the lysosomal enzyme a-Gal A,
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Table 1. Laboratory investigation in Patients 1 and 2 before and after enzyme replacement treatment (ERT)
Patient 1 Patient 2
Before After 15 Before After 15
ERT months ERT months
Hematocrit/hemoglobin % g/dL 34.1/10.3 37.3/11.8 36.1/11.6 37.1/12.1
White blood cells lL 5070 6570 8570 6740
Platelets lL 297,000 300,000 202,000 191,000
Urea mg/dL 142 121 30 31
Creatinine mg/dL 5.7 6.7 1.2 1.1
Glucose mg/dL 87 95 96 81
Uric acid mg/dL 7.4 6.1 9.7 6.8
Sodium/potassium mEq/L 143/4.7 144/4.3 142/4.3 140/4.8
Calcium/phosphate mg/dL 8.7/5.5 9.0/4.3 9.6/3.3 8.8/2.8
ALP/c -GT IU/L 67/15 62/20 70/21 90/14
Transaminase (GOT/GPT) IU/L 11/16 16/11 21/14 26/14
Total bilirubin/direct bilirubin mg/dL 0.4/0.07 0.4 0.9/0.16 0.8
Creatinine kinase/lactic dehydrogenase IU/L 73/498 214/612 111/404 218/477
Proteins/albumin g/dL 6.1/4.0 6.4/3.4 8.3/5.0 7.1/3.6
Total cholesterol/triglycerides/high-density 204/112/45 207/151/51 176/136/38 167/79/41
lipoprotein cholesterol mg/dL
Blood group O O
24-hour urine collection
Volume mL 400 550 2850 2600
Creatinine mg/dL 74 88.6 21 43.9
Protein mg 300 198 110 150
Abbreviations are: ALP/c -GT, alkaline phosphatase/gamma glutamyl transferase; GOT/GPT, glutamic oxalacetic transammase/glutamic pyruvic transaminase.
a glycoprotein of approximately 101 kD with a homod-
imeric structure. The deficiency of a-Gal A results in
the progressive lysosomal accumulation of neutral gly-
cosphingolipids with terminal a-galactosidase residues,
predominantly GL-3. The accumulation of GL-3 occurs
primarily in body fluids and in the lysosomes of many
cells, particularly in renal epithelial cells, endothelial cells,
pericytes, vascular smooth muscle cells, cardiomyocytes,
and neurons of the autonomic nervous system [1]. The
disease is rare: the prevalence in a predominantly white
population is one in 117,000 males [2]; according to an-
other estimate, the disease affects approximately one in
40,000 males [1]. Renal insufficiency is the most frequent
and serious late complication, leading to ESRD and re-
nal replacement therapy. In the past, treatment of Fabry
disease has been symptomatic and directed to palliative
management of disease complications without correcting
the underlying disorder. However, the availability of ERT
remarkably improved the outcome for patients with this
disease. My aim in this Forum is to persuade the reader
that some of the serious complications of Fabry disease,
a previously devastating disease, are curable today, par-
ticularly when the disease is diagnosed early. In this
presentation, I will review the clinical diversity of renal
involvement in Fabry disease and will discuss the effects
of ERT on renal function and pathology.
The gene of a-Gal A, comprised of 7 exons, has been
isolated, sequenced, and localized to the chromosomal
region Xq22.1 [3–6]. To date, a total of 271 mutations
of the gene have been identified in all 7 exons (Human
Gene Mutation Database, http://uwcmmls.uwcm.ac.uk/
uwcm/mg/search/119272.html), including 198 nucleotide
substitutions (missense/nonsense, splicing), 60 microle-
sions (deletions, insertions, indels), and 13 gross lesions
(deletions, insertions and duplications, and complex re-
arrangements). Nevertheless, the crystallographic struc-
ture of the human a-Gal A protein is not yet available,
and only recently was the construction of a model of the
human a-Gal A enzyme achieved [7]. According to this
knowledgeable review, the locations of the human a-Gal
A point mutations reveal two major classes of Fabry dis-
ease protein effects on enzymatic activity: site mutations
and folding mutations. Site mutations reduce enzymatic
activity by perturbing the active site without necessarily
affecting the overall structure of the enzyme; folding mu-
tations destabilize the a-Gal A protein by disrupting its
hydrophobic core. This instability possibly leads to the
mild variant of Fabry disease.
Genetically the disease is described as an X-linked
recessive disorder in which affected males have absent
or very low levels of the lysosomal enzyme a-Gal A.
These patients usually have the so-called classic pheno-
type with onset of the disease during childhood and man-
ifestations that include angiokeratomas, hypohidrosis/
anhidrosis, and acroparesthesias. Later in life, corneal/
lenticular opacities develop as well as major clinical man-
ifestations, such as cardiac involvement (congestive heart
failure, cardiac conduction abnormalities, myocardial in-
farction), and cerebrovascular disease, which includes
dizziness, transient ischemic attacks, and stroke [1]. In
the surviving patients, progressive renal disease leads to
ESRD, which limited the patient’s life span to the early
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forties and was the rule in the absence of dialysis or re-
nal transplantation [8]. It is promising that ERT will not
only substantially increase the life span of these patients
but in time also will reduce their need for dialysis and
transplantation.
Two variants of the classic phenotype are the renal and
cardiac variants. Patients with the renal variant usually
have low plasma a-Gal A activity, a milder phenotype, or
the absence of early presenting symptoms of classic Fabry
disease, but they can reach ESRD and receive dialysis.
According to a recent study, 1% to 2% of ESRD pa-
tients in Japanese, Italian, and American dialysis centers
might have an undiagnosed renal variant of Fabry disease
[abstract; Desnick RJ et al, Nephrol Dial Transplant 17
(Suppl 1):4A, 2002]. Patients with the cardiac variant can
develop late onset cardiac or cardiopulmonary disease
with some degree of proteinuria and renal insufficiency
[9, 10]. It is of note that in male patients with hypertrophic
(mainly concentric) cardiomyopathy in whom the disease
was diagnosed at ≥40 years of age, retrospective clinical
examination revealed the prevalence of Fabry disease to
be 6.3% [11]. Thus, early identification of patients with
both renal and cardiac variants could prevent end-stage
organ damage by early intervention and at the same time
help detect affected relatives.
The third variant of the classic phenotype comprises
heterozygous women from families with the classic phe-
notype. Although most of these women remain asymp-
tomatic and have a normal life span, some experience
a few minor manifestations. Approximately 70% have
whorl-like corneal dystrophy, 30% exhibit a few angiok-
eratomas, and less than 10% suffer from acroparesthe-
sias [1]. Cardiac and renal manifestations in heterozygous
women with Fabry disease are usually lacking. However,
these patients are potential victims for severe organ dam-
age; severe manifestations and death due to heart and
kidney involvement have been reported. The 1995 ERA-
EDTA registry included 10 females among the 83 patients
with Fabry disease who started renal replacement ther-
apy [12]. Similarly, among 95 patients with Fabry disease
who began dialysis between 1985 and 1993 in the United
States, 12% were females [13]. Given these considera-
tions, perhaps Fabry disease should be included in the
differential diagnosis of females with evidence of renal
and/or cardiac involvement, especially those with a pos-
itive family history. The increasing recognition of clini-
cal manifestations of the disease in female heterozygotes
supports the hypothesis that Fabry disease is an X-linked
dominant, and not recessive, disorder [14, 15]. However,
such variable phenotypic expression is expected in fe-
males heterozygous for most X-linked diseases because
of the random inactivation of one X chromosome.
Since most mutations are private, occurring in a
single Fabry disease family, attempts at recognizing
genotype/phenotype correlations have been limited.
Moreover, a variety of phenotypes can occur in identi-
cal hemizygous patients, and the same mutations have
been identified in mild hemizygous patients and severely
affected heterozygous patients. Such observations sug-
gest that other factors are also involved in disease ex-
pression [16]. It is also well known that apart from the
primary disease, genetic or nongenetic factors can influ-
ence the severity and progression of cardiovascular and
renal disease. Whether such factors were involved in the
completely different progression of the renal dysfunction
of the two patients we are considering today is a matter
of discussion. Although the two brothers differ in age by
only 2 years, with the CAPD patient being the younger,
their age at onset of renal failure was similar, they have
the same mutation (T385P on the same exon 7), and
they had comparable, very low plasma a-Gal A activi-
ties. Nevertheless, they exhibited a different progression
of renal dysfunction. This profile contrasts with data from
Branton et al [17], which show that patients with conser-
vative substitution mutations in exons 1, 2, and 5 have a
higher residual a-Gal A level and a later onset of CRI in
comparison to patients with nonconservative mutations
in exons 3, 6, and 7, who have earlier progression of re-
nal insufficiency and absent or low levels of a-Gal A.
However, as the authors stated, their paper has several
limitations: the data were obtained by retrospective chart
review, and the study was not designed to examine renal
manifestations. Different blood groups also might be re-
lated to the severity of disease progression, with blood
groups AB and B associated with a more aggressive dis-
ease course [18]. The blood group of the two brothers we
are discussing is blood group O.
Renal involvement, which starts in early adulthood, is
expressed by an inability to concentrate the urine, pro-
teinuria, and progressive renal failure, which can lead to
ESRD. According to data from the NIH studies [17], 78
of 105 patients with Fabry disease had proteinuria, CRI,
or both. Proteinuria was present at some time in the clin-
ical course of 66 of those 78 patients. The age at onset
of nonnephrotic proteinuria was 34 years (range, 14–55
years). Fifty percent of all Fabry disease patients devel-
oped proteinuria by age 35, and 100% of surviving pa-
tients developed proteinuria by age 52. Nephrotic-range
proteinuria developed in 19 of 78 patients (18%), and the
age at onset was 40 years (range, 26–55 years). The on-
set of nephrotic-range proteinuria did not correlate with
the development of CRI; nephrotic-range proteinuria ap-
peared (with similar percentages) either before or after
CRI, or it did not appear at all. Of 105 patients, 39 de-
veloped CRI. The median age at CRI onset was 42 years
(range, 19–54 years). Twenty four of 105 patients (23%)
developed ESRD at a median age of 47 years (range, 21–
56 years). The time of progression from the onset of CRI
to ESRD was 4 years (range, 1–13 years) in 14 patients for
whom ages at onset for both CRI and ESRD were avail-
able. The same data report a mean decline of glomerular
filtration rate (GFR) of about 12.2 mL/min/year, a value
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comparable to the decline observed in patients with dia-
betic nephropathy who do not receive therapy to block
the renin-angiotensin system [19–21].
A close correlation between blood pressure and the
rate of decline of GFR exists in patients with diabetic
nephropathy [22–24] and in those with a variety of non-
diabetic nephropathies [25]. In one Fabry disease pop-
ulation [17], the prevalence of hypertension was 30%.
According to Branton and colleagues, hypertension was
more likely to be essential or secondary to established re-
nal disease. However, the possibility that increased blood
pressure is a consequence of Fabry disease itself can-
not be disregarded. The two patients we are considering
were hypertensive and had been receiving antihyperten-
sive agents that were discontinued after some months of
ERT even though the patients had gained weight and
their ejection fractions had increased. Although the im-
provement of renal function in the second patient and
CAPD replacement therapy in the first might be respon-
sible for the lowering of blood pressure, an improvement
of the vascular endothelial dysfunction also might be a
possible antihypertensive mechanism.
In support of this speculative mechanism are the find-
ings from studies that confirmed an elevation of markers
of endothelial cell injury and activation. These abnormal-
ities suggest that the vascular endothelial cells of Fabry
disease patients are in a chronic proinflammatory and
prothrombotic state [26, 27]. Also, proteinuria plays a
major role in the progressive loss of GFR in patients with
diabetic and nondiabetic nephropathies [22, 25, 28]. On
the other hand, the role of antihypertensive treatment in
slowing the decline of GFR is documented by long-term
clinical studies both in patients with diabetic nephropathy
[19, 29] and nondiabetic nephropathies [25]. The benefi-
cial effect of ACE inhibitors on proteinuria and the rate
of decline in GFR, mainly in type 1 diabetic nephropathy
[30, 31] and nondiabetic nephropathies [26], is well rec-
ognized, and as Bjorck et al [32] suggested, this beneficial
effect on renal function and structure is above and beyond
that expected from the blood pressure reduction alone. It
is of interest that Patient 1 had received an ACE inhibitor
since the onset of his CRI. Although a delay in the de-
cline of renal function was observed, renoprotection was
not achieved, possibly because of his long-lasting, perma-
nent, severe proteinuria. Compatible with this patient’s
case are the results of a recent study showing that 42%
of patients with nondiabetic renal disease escape the an-
tiproteinuric effect of ACE inhibitors and subsequently
develop an exacerbation of renal dysfunction [33].
Kidney biopsies in patients with Fabry disease have
shown extensive accumulation of GL-3 in nearly all renal
cell types, but it varies considerably in quantity and mor-
phology among the different cells. In a well-conducted
and detailed histologic study, Thurberg et al analyzed
pre- and post-ERT renal biopsy data from 58 FD pa-
tients (56 males, 2 females) [34]. Of these patients, one-
half received treatment for 6 months, the other half 11
months. At baseline, podocytes and epithelial cells of
distal convoluted tubules and collecting ducts contained
the highest concentrations of GL-3 deposits; proximal
tubular epithelial cells were relatively unaffected. Vas-
cular endothelial and smooth muscle cells as well as
mesangial and interstitial cells also accumulated moder-
ate amounts of GL-3. Lipid-laden distal tubular epithelial
cells desquamate and can be detected in the urine [35].
In later stages of the disease, the histologic findings cor-
respond to those of ESRD, with severe arteriolar and
glomerular sclerosis, tubular atrophy, and diffuse inter-
stitial fibrosis [1]. According to Gubler et al [36], these
lesions might be related to ischemic changes due to necro-
sis of smooth muscle cells fatally overloaded with GL-3
deposits. However, podocyte injury due to toxic accumu-
lation of GL-3 and tubulointerstitial injury could consti-
tute two other important mechanisms that lead to ESRD
[37]. Lipid material in epithelial cells of the glomeruli
and within tubular epithelial cells and the interstitium
also was detected in a renal biopsy from a patient with
Fabry disease who did not have the typical skin lesions
[38].
Enzyme replacement therapy with recombinant a-Gal
A became available recently and two placebo-controlled
clinical trials were published in 2001. In the first trial [39],
agalsidase alfa (Replagal), a human cell line product, was
administered intravenously every 14 days at a dose of
0.2 mg/kg/body weight for 24 weeks (12 infusions) to
26 hemizygous male patients. Although the evaluation
of renal function was not the main outcome measure,
the investigators found an improvement in glomerular
histology in patients treated with agalsidase alfa. There
was a 21% increase in the fraction of normal glomeruli
(glomeruli without mesangial widening or sclerosis) in
treated patients, whereas a 27% decrease in the fraction
of normal glomeruli was observed in patients random-
ized to placebo (P = 0.01). The authors also noted a
decrease in glycolipid inclusions within the vascular en-
dothelium in the treated group compared to an increase
in the placebo group. Renal function was assessed by
Ccr and inulin clearance in 13 patients undergoing ac-
tive treatment and in 11 of the placebo group. Both tests
showed a trend in favor of enzyme treatment. There was
no consistent change in urinary protein excretion in 5 of
the patients from the active treatment group and in 3 from
the placebo group who had proteinuria >1 g/24 hours.
The second study included 58 patients (56 males and
2 females) who received agalsidase beta (Fabrazyme),
which is produced in a hamster cell line [40]. Twenty-
nine patients received the drug intravenously in a dose
of 1 mg/kg/body weight; the other 29 received placebo
every 14 days. The patients had normal or slightly im-
paired renal function. The primary end point was the
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disappearance (“0” score) of microvascular endothelial
GL-3 deposits in renal biopsy specimens after 20 weeks of
treatment (11 infusions). Of 29 patients in the active treat-
ment group, 20 (69%) reached this end point compared
to none in the placebo group. Thereafter, all patients
were enrolled in an open label extension study. After 6
months of treatment with recombinant agalsidase beta,
98% of patients in whom a biopsy was performed (42 of
43) had a score of 0 on histologic analysis of microvascular
endothelial deposits of GL-3 in kidney specimens. Gly-
colipid completely disappeared from the endothelium of
all vasculature as well as from the mesangial cells of the
glomerulus and interstitial cells of the cortex. Moderate
reduction was noted from the smooth muscle cells of ar-
terioles and small arteries. Podocytes and distal tubular
epithelium also demonstrated decreased GL-3, although
this reduction was more limited than that observed in
other cell types. No evidence of immune complex dis-
ease was found by immunofluorescence despite circulat-
ing anti-r-ha-Gal A IgG antibodies [34]. Baseline serum
creatinine and GFR were normal (treatment group,
0.8 ± 0.2 mg/dL and 83 ± 22.0 mL/min; placebo group,
0.8±0.2 mg/dL and 96.6±35.3 mL/min, respectively) and
did not change substantially in either group after week 20
of the double-blind study (P = 0.19) or after 6 months of
the open-label treatment (P = 0.81). The safety and ef-
ficacy of ERT have been demonstrated with the two en-
zyme formulations, and both the ERT and placebo groups
experienced significant improvement in the severity of
pain and quality of life. Plasma and urine concentration
of GL-3 decreased significantly in the treated groups of
both studies in contrast to patients who received placebo.
In Patient 2 under discussion today, a gradual increase
in Ccr was noticed after 6 months of ERT. This impor-
tant finding suggests that in a Fabry disease patient with
CRI and without overt proteinuria, ERT can reverse the
decline of renal function. Moreover, Patient 1 also had
a slight increase of residual renal function. Proteinuria,
on the other hand, is a marker of podocyte injury and,
as I already mentioned, the removal of GL-3 from the
podocytes was limited compared to that in other cells.
This is possibly the reason why proteinuria did not change
in the 5 patients who received ERT with agalsidase beta
[39].
In conclusion, I would argue that early therapeutic in-
tervention with ERT for renoprotection in patients with
Fabry disease is effective and safe. Although renal trans-
plantation successfully corrects renal failure and the graft
is protected by itself because its cells have the ability to
produce the enzyme, ERT also might confer benefit to
transplant and dialysis patients in protecting other vital
organs. However, no available studies support this argu-
ment at the moment; future experience will show whether
this treatment is efficient and cost-effective.
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Dean ad Interim, Tufts
University School of Medicine, Boston, Massachusetts,
USA): Considering the different clearance of GL-3 de-
posits from various cells, what do we know about the
mechanisms of recombinant a-Gal A entry into various
cells? What information do we have about tissue kinetics
of the enzyme?
DR. SIAMOPOULOS: Studies on the synthesis of a-Gal
A in cultured human cells have shown that the enzyme
is synthesized as a precursor peptide that is processed
in the mature lysosomal subunit [41, 42]. After intra-
venous administration, the enzyme is rapidly removed
from the circulation and taken up by vascular endothe-
lial and parenchymal cells into the lysosomes. The trans-
portation to the lysosomes is dependent on the mannose-
6-phosphate receptors located at the plasma membrane
of the cells. Initial studies with different recombinant a-
Gal A glycoforms, as regards their glycosylation and/or
phosphorylation, showed that at doses of 1 to 10 mg/kg
body weight, more than 90% of recovered enzyme activ-
ity of all four glycoforms was found in the liver and spleen,
with 1% to 3% recovered in the heart and kidney, and
none detectable in the brain. The half-life in plasma was
less than 5 minutes for each glycoform [1]. Single doses
of administered a-Gal A (0.3 to 10.0 mg enzyme/kg body
weight) demonstrated that the reduction of GL-3 in liver,
spleen, heart, and kidney is dose-dependent [43]. In an
open-label, dose-escalation study of agalsidase beta treat-
ment in 15 patients, each of whom received 5 infusions at
one of the 5 dose regimens, clearance of the enzyme from
the circulation appeared to be biphasic for all biweekly
dose groups, with the more rapid elimination phase last-
ing 1 to 2 hours after the infusion [44]. In patients with
pre- and post-treatment biopsies, mean GL-3 content was
decreased by 84% in the liver, markedly reduced in the
kidney in 4 of the 5 patients and, after 5 doses, was
modestly lowered in the endomyocardium of 4 of the 7
patients.
DR. AIKATERINI PAPAGIANNI (Lecturer in Nephrol-
ogy, Medical School, Aristotelion University of Thessa-
loniki, Thessaloniki, Greece): The persistence of GL-3
accumulation in podocytes in the study you mentioned
is at least partly due to the extremely low turnover of
these cells and underlies the need for longer treatment
(more than 11 months) to achieve significant clearance
of the deposits. However, does the extent of GL-3 accu-
mulation in podocytes, and therefore the degree of pro-
teinuria, play an important role in the development of
renal function impairment? We know that there are het-
erozygous asymptomatic females with extensive deposits
in podocytes but well-preserved renal function for a long
period. Could you comment on this?
750 Nephrology Forum: Fabry disease
DR. SIAMOPOULOS: Podocytes are highly differenti-
ated cells and, along with parietal epithelial cells, have
the slowest turnover rate among the renal cell popula-
tions [45–47]. On the other hand, podocytes are among
the cells with the greatest glycolipid inclusions. The
combination of slow turnover with the high rate of
endogenous substrate generation and the relatively short
duration of treatment, along with an anticipated difficulty
of the enzyme to pass through various cellular and acellu-
lar renal tissue barriers to reach the podocytes, most likely
explains the low clearance of GL-3. Apart from the very
well known role of severe proteinuria in the development
and progression of renal failure, on which I have already
commented, it seems that the accumulation of GL-3 in
podocytes alone is not enough to cause severe renal dys-
function. As you mentioned, heterozygous females with
significant accumulations of GL-3 in the podocytes have
little alteration in renal function [48–51].
DR. JOHN PAPADAKIS (Director, Renal Unit, General
Hospital “Thriasion” of Elefsina, Athens, Greece): Could
you please tell us what criteria we should use in deciding
whether to order a renal biopsy?
DR. SIAMOPOULOS: Patients with normal renal func-
tion and mild proteinuria have a substantial accumula-
tion of GL-3 in renal biopsies. Therefore, renal biopsy
is recommended in patients with significant protein-
uria (300 mg/24 hours). Besides, most patients in two
placebo-controlled trials [39, 40] had normal renal func-
tion or some degree of renal insufficiency with signifi-
cant GL-3 deposits in the biopsied renal tissue. In the
absence of significant proteinuria or renal insufficiency,
and if the diagnosis of Fabry disease is difficult to es-
tablish, a renal biopsy should be considered, either to
make the diagnosis or to exclude co-existing renal dis-
ease. In 19% of patients without a family history of
Fabry disease, the diagnosis was made by nephrologists
[17].
DR. AIMILIOS ANDRIKOS (Registrar in Nephrol-
ogy, Department of Nephrology, General Hospital “G.
Hatzikosta” of Ioannina, Ioannina, Greece): Are there
any guidelines regarding the initiation of enzyme replace-
ment therapy?
DR. SIAMOPOULOS: According to one recent review
[52], ERT should be initiated in all patients with Fabry
disease. Treatment ideally should begin as soon as clini-
cal signs and symptoms, such as pain or isosthenuria, are
observed. Affected children and carriers with substantial
disease manifestations also should be treated. Patients
undergoing dialysis and those who have received a kidney
transplant are at high risk for cardiac and cerebrovascu-
lar complications; this is why ERT is also recommended
in these patients.
DR. CHRISTOS IATROU (Director, Center for Nephrol-
ogy “G. Papadakis,” General Hospital of Nikea, Piraeus,
Greece): In the case of a patient with Fabry disease and
significant proteinuria who doesn’t respond to the sug-
gested doses of ERT, would you add an ACE inhibitor or
increase the dose of the enzyme?
DR. SIAMOPOULOS: As I mentioned earlier, the benefi-
cial effect of an ACE inhibitor on proteinuria and the rate
of decline in GFR in diabetic [30, 31] and non-diabetic
nephropathies [26] is well recognized, and this beneficial
effect on renal function and structure is above and be-
yond that expected from the blood pressure reduction
alone [32]. It is of interest that the CAPD patient I pre-
sented was receiving an ACE inhibitor since the onset of
CRI. Although he reached ESRD, a delay in the decline
of renal function was observed (rate of decline of renal
function of approximately 7.9 mL/min/year). No data are
available on the efficacy of ACE inhibitors or angiotensin
receptor blockers in delaying the progression of Fabry re-
nal disease. Extrapolating the results from the use of such
drugs in other nephropathies, I could suggest that their
administration in combination with ERT is a reasonable
medical practice. The increase of the dose of the enzyme is
in fact a matter of discussion, because the optimal doses
for the reversal, maintenance, and prevention of GL-3
accumulation in the kidney, heart, and vasculature are
unknown. Perhaps higher doses or longer treatment are
required to clear the massive accumulation of GL-3 in
podocytes.
DR. IATROU: If the patient’s body weight is low, as in
the case of the first patient (50 kg), and since each vial of
Fabrazyme contains 30 mg of the enzyme, an expensive
drug, how can we use the remaining amount of the drug
from the second vial? Can we administer it to the patient
or should we discard it?
DR. SIAMOPOULOS: The results of the phase I-II dose-
escalation clinical trial [44] indicated that the clearance of
GL-3 from tissue lysosomes was dose-dependent. There-
fore, I see no reason in discarding the rest of the enzyme,
especially in a patient with severe cardiomyopathy. Like
podocytes, cardiomyocytes also are resistant to GL-3
clearance by ERT.
DR. IATROU: What are the guidelines for the dosage?
Are the levels of GL-3 in the blood an appropriate and
sensitive index?
DR. SIAMOPOULOS: According to a recent review of
clinical guidelines [52], doses of 0.2 mg/kg for agalsi-
dase alpha (Replagal) and 1 mg/kg for agalsidase beta
(Fabrazyme) every 2 weeks are recommended. Patients
receiving ERT should be followed at least once annu-
ally. If plasma GL-3 levels prove to be a useful marker of
the disease burden and treatment efficacy, a goal of ther-
apy should be to normalize plasma levels. For children,
monitoring the frequency and severity of peripheral pain
and gastrointestinal symptoms also could indicate clinical
effectiveness.
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DR. MADIAS: Are patients with no detectable endoge-
nous protein at a higher risk of developing an immune
response to exogenous enzyme? Do anti-a-Gal A anti-
bodies have neutralizing activity? What is the significance
of these antibodies regarding the effectiveness and safety
of ERT?
DR. SIAMOPOULOS: Seroconversion rates, with largely
IgG antibodies, in the two placebo-controlled trials were
64% for agalsidase alpha [39] and 88% for agalsidase beta
[40]. Patients with the classic phenotype have low or un-
detectable levels of enzyme, so the antibody reponse is
expected to be high. However, no evidence exists that an-
tibody formation alters the efficacy of enzyme treatment;
this hypothesis is based on the continued reduction in
histologic scores for cellular clearance of GL-3 even in
patients who developed transiently higher titers [40]. Pa-
tients with IgG antibodies might have a higher risk of
hypersensitivity reactions such as fever/chills, headache,
chest pain, and dyspnea. The available evidence suggests,
however, that over time, the number of patients experi-
encing infusion reactions to agalsidase beta is reduced to
10% to 20% [53].
DR. MADIAS: What are the prospects of alternative
therapies in Fabry disease, namely gene therapy, as well
as inhibition of synthesis or accumulation of GL-3?
DR. SIAMOPOULOS: A number of other therapeutic en-
deavors have been attempted [1]. A variety of inhibitors
to deplete the accumulated GL-3 have been used exper-
imentally [54]. Although a reduction of GL-3 in lym-
phoblasts was found in vitro, the safety and efficiency
of these compounds have not been clinically evaluated.
Depletion of GL-3 from the circulation also was achieved
by plasmapheresis, with the plasma substrate levels re-
turning to pre-plasmapheresis levels in 5 days [55].
Chronic plasmapheresis, however, is not yet acknowl-
edged as an important intervention for the therapy of
Fabry disease. Finally, for cardiac variant patients with
residual a-Gal A activity, the use of competitive inhibitors
such as “chemical chaperons” at subinhibitory intracellu-
lar concentrations might prove efficacious. The prospect
of gene therapy in Fabry disease is promising. After the
early experimental studies that focused on the construc-
tion of retroviral and other vectors that expressed the
a-Gal A cDNA in vitro, treatment with the recombinant
adenoviral vector of Fabry knockout mice increased the
a-Gal A activity in all tissues analyzed, including the liver,
lung, spleen, muscle, heart, and kidney [56]. However, ex-
pression of a-Gal A did not persist, although a decrease
of the accumulated GL-3 to nearly normal levels for as
long as 6 months after treatment was found in the tissues
studied. With time, overcoming some of the initial limi-
tations will give the green light for gene therapy in Fabry
disease patients.
DR. ANDREAS ZOURIDAKIS (Director, Renal Unit,
General Hospital of Filiates, Thesprotia, Greece): Could
liver transplantation in early Fabry disease provide a suf-
ficient amount of a-Gal A to the patient?
DR. SIAMOPOULOS: Following transplantation of fetal
liver in 3 hemizygotes with Fabry disease, the a-Gal A
levels in serum and leukocytes remained unchanged, and
the GL-3 levels in urine and serum slightly decreased [57].
As far as bone marrow transplantation is concerned, no
data are available in humans. Normal murine bone mar-
row transplantation into a-Gal A-deficient mice lowered
the concentration of GL-3 in the liver, spleen, and heart,
but not in the kidney [58] [abstract; Simonara CM et al,
Am J Hum Genet 65:A503, 1999].
DR. VASSILIOS VARGEMEZIS (Professor of Nephrol-
ogy, Medical School, Dimocritus University of Thrace,
Thrace, Greece): What are the kinetics of the enzyme
after its administration in patients on hemodialysis or
peritoneal dialysis? Is there any loss from the dialyser
or peritoneal membrane?
DR. SIAMOPOULOS: Administration of the enzyme dur-
ing hemodialysis does not change the kinetics or efficacy
of agalsidase beta in patients with Fabry disease. Accord-
ing to a recent study [abstract; Kosch M, et al, Nephrol
Dial Transplant 18:632, 2003], replacement therapy with
recombinant human agalsidase beta performed in the in-
tervals between dialysis or during hemodialysis resulted
in no loss of enzyme activity into the dialysate using ei-
ther low- or high-flux dialyzers. Similarly, the amount
of enzyme lost in the peritoneal fluid is minimal (about
3.0 lg) and is mainly detected in the first 2 dialysate drain-
ing bags (personal data).
DR. DIMITRIOS TSAKIRIS (Consultant Nephrologist,
Director, Department of Nephrology, General Hospital of
Veria, Veria, Greece): Experience from the ERA-EDTA
Registry showed that transplantation is not contraindi-
cated in patients with Fabry disease, as both graft and
patient survival were comparable to graft and patient sur-
vival in patients with other primary renal diseases [12].
That study, however, did not show meaningful results with
regard to two points: (1) improvement of a-Gal A activ-
ity after transplantation, and (2) possible recurrence of
the disease in the graft. Could you comment on these
two points? Also, do Fabry disease patients with a renal
transplant benefit from ERT?
DR. SIAMOPOULOS: The paper you mentioned [12]
along with another more recent report from the United
States Renal Data System registry [60] indicate a clear
benefit of transplantation in Fabry disease with excellent
outcomes. Successful renal transplantation corrects renal
function, and the engrafted kidneys function normally
for several years in the absence of clinical signs or loss
due to recurrence [60, 61], although isolated GL-3 de-
posits have been detected histologically [62]. However,
although the normal a-Gal A activity of the graft catabo-
lizes endogenous renal glycosphingolipid substrates, the
enzyme is ineffective in correcting the systemic metabolic
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abnormality [6]. Transplantation of kidneys from Fabry
carriers should be avoided, as these grafts can contain
GL-3 deposits.
Regarding your question about ERT in these patients,
no studies have been reported of ERT in patients with
Fabry disease who have received a kidney transplant or
who are undergoing dialysis. According to a recent small
study [abstract; Mignani R, et al, Nephrol Dial Transplant
18:633, 2003] in 6 patients with Fabry disease and cadav-
eric kidney transplantation who received agalsidase beta
mainly for severe cardiomyopathy, ERT was found to
be safe and effective and yielded improvement of symp-
toms, such as pain, and echocardiographic findings such
as LVH.
DR. TSAKIRIS: Is there an international registry for
Fabry disease patients that coordinates the answers to
the many questions raised in this new era of ERT? The
disease is very rare, the therapy is very costly, and it is ap-
plied by more than one specialty. Only an international
registry will provide meaningful answers to novel ques-
tions and assist in the planning of prospective studies.
DR. SIAMOPOULOS: Thank you for this interesting
comment. Recently a web-based, central data collection
system was developed and a registry program established
(www.fabryregistry.com). The objective of the Fabry reg-
istry is to (1) enhance the understanding of the variability,
progression, and natural history in males and females, in-
cluding the development of recommendations for moni-
toring patients; (2) optimize patient care; and (3) evaluate
long-term effectiveness of ERT [abstract; Wanner C,
et al, Nephrol Dial Transplant 18:634, 2003].
DR. ALKIS PIERIDES (Consultant Nephrologist; Di-
rector, Department of Nephrology, General Hospital of
Nicosia, Cyprus): What is the optimal diagnostic ap-
proach for women from families with classic Fabry
disease?
DR. SIAMOPOULOS: The detection of a female carrier
by the a-Gal A assay is not reliable because some obligate
heterozygotes have normal a-Gal A activity. Therefore,
all females at risk for carrying the gene of Fabry disease
should have molecular studies to detect the family’s pri-
vate mutation [52].
This Nephrology Forum was held at the Bourazani
Environmental Park and Conference Center, Bourazani,
Greece.
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